Mukesh K. Nyati

Also affiliated with Michigan United, Michigan Medicine

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts”.

Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3102

N/A

0DataRank · unranked

22 citations

Sanjima Pal, Koushik Kondapi, Merna Sitto, Cuyler Dewar, Theresa P. Devasia +10 more

Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin

Head & Neck(2020)10.1002/hed.26085

N/A

0DataRank · unranked

8 citations

Pin Li, Emily L. Bellile, Chaz L. Stucken, Kelly M. Malloy, Andrew G. Shuman +15 more

Mutant EGFR is a preferred SMURF2 substrate of ubiquitination: role in enhanced receptor stability and TKI sensitivity

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.04.02.022012

N/A

0DataRank · unranked

0 citations

Krishnan Raghunathan, Aarif Ahsan, Uday Sankar Allam, Shirish Shukla, Venkatesha Basrur +5 more

Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab

Molecular Therapy(2021)10.1016/j.ymthe.2021.06.009

N/A

0DataRank · unranked

23 citations

Min Liu, Emily L. Bellile, Ligia B. Schmitd, Mitsuo Goto, Marsha-Kay Hutchinson +11 more

Disruptin, a cell-penetrating peptide degrader of EGFR

Translational Oncology(2021)10.1016/j.tranon.2021.101140

N/A

0DataRank · unranked

8 citations

Sushmita Shukla, Susmita G. Ramanand, Vishal Somnay, Alexander J. Bridges, Theodore S. Lawrence +2 more

Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer

Head & Neck(2023)10.1002/hed.27344

N/A

0DataRank · unranked

11 citations

Megan Ludwig, Apurva D. Bhangale, Collin Brummel, Paul Swiecicki, Francis P. Worden +17 more

Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization

Aging(2023)10.18632/aging.204820

N/A

0DataRank · unranked

8 citations

Grant M. Young, Corey Speers, Mukesh K. Nyati, Alnawaz Rehemtulla, Shyam Nyati

Data from Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer

(2023)10.1158/1078-0432.c.6519774.v1

N/A

0DataRank · unranked

0 citations

Austin G. Duffy, Shivaani Kummar, Nicole L. Simone, Yoshio Arai, Seungwon W. Kim +13 more

A molecularly engineered lectin destroys EGFR and inhibits the growth of non-small cell lung cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.18.585535

N/A

0DataRank · unranked

2 citations

Zoe Raglow, Anupama Pal, Scott D. Gitlin, Maureen Legendre, Dafydd G. Thomas +6 more